Company Overview and News

 
New age takeover: Debit card PoS transactions of Airtel, Paytm, Fino Payments banks beat those of mid-sized PSBs!

2018-10-14 financialexpress
The volume of point-of-sale (POS)-based transactions reported by debit card users of three payments banks—Airtel Payments Bank, Fino Payments Bank and Paytm Payments Bank — is now higher than those made by debit card holders of some mid-sized public sector banks (PSBs), data from the Reserve Bank of India (RBI) showed.
532121 UDBKL UBLA UBLS TCHQY DENABANK 532755 TECHM 532401 VIJAYABANK

 
RBI#39;s corrective action on 12 banks limited losses, saved taxpayer money: Viral Acharya

2018-10-12 moneycontrol
Prompt Corrective Action (PCA) imposed on 12 banks has limited their losses and saved taxpayer money, according to the central bank’s Deputy Governor Viral Acharya.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

 
Asia Frontier Capital - Pakistan Travel Report

2018-10-12 seekingalpha
In line with our process of being on the ground in the countries we invest in, Fund Manager and CEO Thomas Hugger travelled to Pakistan recently in order to meet with management of portfolio or shortlisted companies. All photos are by Asia Frontier Capital.
UDBKL UBLA UBLS PAK LUCKY LKCA LKCS

 
People's United (PBCT) Q3 Earnings Preview: Here's What to Look Out For

2018-10-11 zacks
The market expects People's United (PBCT - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
UDBKL UBLA UBLS

 
United Financial (UBNK) Q3 Earnings Preview: What to Know Ahead of the Release

2018-10-09 zacks
The market expects United Financial (UBNK - Free Report) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
UDBKL UBLA UBLS

 
United Bank of India - Updates

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

 
United Bank of India - Updates

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

 
United Financial Bancorp, Inc. (UBNK) Announces Dates for Q3 2018 Earnings Release and Conference Call

2018-10-02 globenewswire
HARTFORD, Conn., Oct. 02, 2018 (GLOBE NEWSWIRE) -- United Financial Bancorp, Inc. (“United Financial” or the “Company”) (NASDAQ Global Select Stock Market: “UBNK”), the holding company for United Bank (the “Bank”), today announced that it expects to release financial results for the third quarter ending September 30, 2018 (Q3 2018) on Tuesday, October 16, 2018, after 4:00 pm Eastern Time (ET). A copy of the earnings release will immediately be made available on the Company’s website at www.
UBNK UDBKL UBLA UBLS

 
United Bank of India - Change in Director(s)

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

 
People's United-First Connecticut Deal Gets Shareholder Nod

2018-09-27 zacks
The merger of People’s United Financial (PBCT - Free Report) and First Connecticut Bancorp (FBNK - Free Report) announced in June 2018 has been approved by shareholders of the to-be-acquired company at a special meeting held on Sep 25. Along with this, the companies announced the receipt of all the necessary regulatory approvals for the buyout, which is expected to close on Oct 1.
HFWA FBNK BANR DB UDBKL UBLA UBLS

 
First Connecticut Bancorp, Inc. Stockholders Approve Acquisition by People’s United Financial, Inc.

2018-09-26 globenewswire
FARMINGTON, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Stockholders of First Connecticut Bancorp, Inc. (“First Connecticut”) (NASDAQ:FBNK) approved the proposed merger of First Connecticut and People’s United Financial, Inc. (“People’s United”) (NASDAQ:PBCT) pursuant to the previously disclosed Agreement and Plan of Merger, dated as of June 18, 2018 (the “Merger Agreement”) at First Connecticut’s special meeting of stockholders held on September 25, 2018.
FBNK UDBKL UBLA PBCT UBLS

4
The Connecticut Institute for Refugees and Immigrants honors Ethan Allen’s Farooq Kathwari

2018-09-24 globenewswire
DANBURY, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Connecticut Institute for Refugees and Immigrants (CIRI) honored Farooq Kathwari, Chairman, President and CEO of Danbury-based Ethan Allen Interiors Inc., with its Legacy Award at a gala dinner in Westport, CT., on September 23.
UDBKL UBLA UBLS SYF

 
United Bank of India - Change in Director(s)

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

 
Should Investors Exit International Stocks?

2018-09-24 seekingalpha
Foreign stocks have trailed badly behind US stocks so far in 2018, leading some investors to question whether they should maintain foreign exposure in their portfolios.
UDBKL UBLA UBLS

 
United Bank of India - Appointment

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...